Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 325 publications.

Ainsworth C, Higuchi K, Simou E, Guyot P, Greene N. Relative differences in brain volume loss with teriflunomide versus other disease-modifying therapies in relapsing multiple sclerosis: a systematic review and network meta-analysis. Poster presented at the ACTRIMS Forum 2022; February 24, 2022. West Palm Beach, FL.

Lewis S, Wray SE, Evans E, Romano (DeMuro) C, Bartolome L, Su W, Shah R, Russo PA. Patients' experiences in transitioning to secondary progressive multiple sclerosis: qualitative interviews. Neurol Ther. 2021 Dec;10(2):887-904. doi: 10.1007/s40120-021-00265-0

Herring WL, Gould IG, Fillit H, Lindgren P, Forrestal F, Thompson R, Pemberton-Ross P. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer's disease. Neurol Ther. 2021 Dec;10(2):919-40. doi: 10.1007/s40120-021-00273-0

Clinch S, McDougall F, Barrett A, Olayinka-Amao B, Craveiro L, Baker M, Lindemann M. Understanding MS symptoms and impacts through semi-structured interviews with clinical experts and people living with MS. Poster presented at the 2021 CMSC Annual Meeting; October 25, 2021. Orlando, FL.

Serbin M, Mansfield C, Sheehan M, Donnelly A. Development of a patient survey on preferences for adjunctive parkinson's disease medications: results from pretest interviews. Poster presented at the 2021 OAAPN Statewide Conference; October 21, 2021. Columbus, OH. Previously presented at the AMCP Nexus 2021.

Clinch S, McDougall F, Barrett A, Olayinka-Amao B, Craveiro L, Baker M, Lindemann M. A patient-focused qualitative study to support content validity of digital performance assessments in MS. Poster presented at the 2021 ECTRIMS Annual Congress; October 13, 2021. [abstract] Mult Scler J Exp Transl Clin. 2021 Oct 21; 27(2 Suppl):329. doi: 10.1177/13524585211044667

Hellwig K, Magyari M, McDonald T, Gembert K, Wergeland S, Leinonen MK, Aydemir A, Sabido M, Kawai A, Arana A. A multi-country cohort database study to assess pregnancy and infant outcomes in women exposed to cladribine tablets: CLEAR study. Poster presented at the 2021 Digital 37th Conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13, 2021.

Klepitskaya O, Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Sheehan M, Donnelly A. Development of a patient survey on preferences for adjunctive parkinson's disease medications: results from pretest interviews. Poster presented at the AMCP Nexus 2021; October 18, 2021. [abstract] J Manag Care Pharm. 2021 Oct; 27(10-a):S8.

Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Evaluating patients' preferences for parkinson's disease treatments. Poster presented at the MDS Virtual Congress 2021; September 17, 2021. [abstract] Mov Disord. 2021 Sep; 36(S1).

Johannes CB, Saltus CW, Kaye JA, Calingaert B, Kaplan S, Gordon MF, Andrews EB. The risk of melanoma with rasagiline compared with other antiparkinsonian medications: a retrospective cohort study in the United States Medicare database. Presented at the Virtual ICPE 2021 Conference; August 24, 2021.

Saltus CW, Kaplan S, Gordon MF, Calingaert B, Andrews EB, Kaye JA, Johannes CB. Validation of diagnosis algorithms for melanoma and nonmelanoma skin cancer among patients with parkinson's disease in the United States Medicare Database. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Brandt T, Frangiosa T, Biggar V, Taylor A, Valentine J, Keller B, Price M, DeMuro C, Abler V. Symptoms and treatment needs of people with dementia-related psychosis: a mixed-methods study of the patient experience. Clin Gerontol. 2021 Aug 9;45(3):681-95. doi: 10.1080/07317115.2021.1957050

Thach A, Sutphin J, Coulter J, Leach C, Pappert E, Mansfield C. Patient preferences for treating “OFF” episodes in parkinson's disease: a discrete choice experiment. Patient Prefer Adherence. 2021 Jun 1;2021(15):1187-96. doi: 10.2147/PPA.S301644

Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic review. Adolesc Health Med Ther. 2021 May 19;12:55-66. doi: 10.2147/AHMT.S303456

Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664

Herring W, Garrison L, Phelps C, Basu A. Challenges in assessing the clinical and economic value of future treatments for Alzheimer's disease. Presented at the 2021 ISPOR Educational Webinar; February 26, 2021.

Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021 Jan 27. doi: 10.1371/journal.pone.0246121

Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Evaluating patients' preferences for Parkinson's disease treatments. Poster presented at the 146th 2021 American Neurological Association (ANA) Virtual Meeting; October 17, 2021. [abstract] Ann Neurol. 2021; 90(S27):S151-2.

Herring W, Gould I, Haines P, Thompson R, Pemberton-Ross P. Predicted delays in dementia onset for an innovative therapy acting on beta-amyloid in patients with mild cognitive impairment due to Alzheimer's disease. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Thach A, Sutphin J, Coulter J, Mansfield C. Preferences for on-demand treatments for Parkinson's disease–related "OFF" episodes: a discrete-choice experiment. Poster presented at the 2020 Virtual AMCP NEXUS; October 19, 2020. Previously presented at the 2020 ISPOR Virtual Conference.

Herring W, Benham-Hermetz S, Gustavsson A, Hayek Y. Assessing the value of delayed progression in early Alzheimer's disease: what are the critical issues? Presented at the HTAi 2020 Virtual Annual Meeting; October 13, 2020.

Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Thach A, Sutphin J, Coulter J, Mansfield C. A discrete-choice experiment evaluating preferences for on-demand treatments for patients with Parkinson's Disease and “OFF” episodes. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427. doi: 10.1002/mds.28268

Thach A, Coulter J, Leach C, Sutphin J, Mansfield C. On-demand treatment preferences of patients with Parkinson's Disease and “OFF” episodes: heterogeneity across patient subgroups. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427-8. doi: 10.1002/mds.28268

Penner I-K, McDougall F, Brown TM, Slota C, Doward L, Julian L, Belachew S, Miller D. Exploring the impact of fatigue in progressive multiple sclerosis: a mixed-methods analysis. Mult Scler Relat Disord. 2020 Aug;43:102207. doi: 10.1016/j.msard.2020.102207

DiBenedetti D, Slota C, Wronski SL, Vradenburg G, Comer M, Callahan LF, Winfield J, Rubino I, Krasa HB, Hartry A, Wieberg D, Kremer IN, Lappin D, Martin AD, Frangiosa T, Biggar V, Hauber B. Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020 Jul 30;12(90). doi: 10.1186/s13195-020-00659-6

Hartry A, Menne H, Wronski S, Paulson R, Callahan L, Potashman M, Lee D, Wunderlich G, Hoffman D, Wieberg D, Kremer I, Hauber B, DiBenedetti D. Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's Disease. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 29, 2020.

Hauber B, Paulsen R, Callahan L, Potashman M, Lee D, Hartry A, Wunderlich G, Hoffman D, Wieberg D, Kremer I, DiBenedetti D. Quantifying what matters most to patients and care partners in Alzheimer's Disease. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 29, 2020.

Majid T, Paulsen R, Callahan L, Potashman M, Lee D, Hartry A, Wunderlich G, Hoffman D, Wieberg D, Kremer I, Hauber B, DiBenedetti D. The importance of care partner input in Alzheimer's Disease (AD) drug development. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 27, 2020.

Herring WL, Mauskopf J. Persistent challenges in Alzheimer's disease modeling: pragmatic solutions to inform the road forward. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 2020.

Shah S, Sacco P, Jackson L, Price M, Bensink M, Bernstein C. Beyond frequency alone - exploring what meaningful improvement means in the treatment of migraine: focus groups in patients and health care providers. Poster presented at the 2020 American Headache Society 62nd Virtual Annual Scientific Meeting; June 15, 2020. San Diego, CA.

Poulos C, Hauber B, Mirzaei F, Dilley A, DeMuro C, Fillit HM. A study of preferences for disease-modifying treatments for Alzheimer's Disease. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S278. doi: 10.1016/j.jval.2020.04.991

Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen S. Impact of neurofibromatosis type 1 and plexiform neurofibromas on patient-reported health-related quality of life. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S344. doi: 10.1016/j.jval.2020.04.371

Thach A, Sutphin J, Coulter J, Mansfield C. Preferences for on-demand treatments for Parkinson's disease–related "OFF" episodes: a discrete-choice experiment. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S325. doi: 10.1016/j.jval.2020.04.094

Thach A, Sutphin J, Coulter J, Mansfield C. Patient experiences and preferences for specific on-demand treatments for Parkinson's Disease-related “OFF” episodes. Poster presented at the 2020 AMCP (Conference cancelled); April 21, 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr; 26(4-a):S40.

Poulos C, Wakeford C, Kinter E, Mange B, Schenk T, Jhaveri M. Patient and physician preferences for multiple sclerosis treatments in Germany: a discrete-choice experiment study. Mult Scler J Exp Transl Clin. 2020 Jan;9(2):1-14. doi: 10.1177/2055217320910778

Hauber B, DiBenedetti D, Vradenburg G, Callahan L, Potashman M, Krasa H, Hartry A, Wunderlich G, Hoffman D, Wieberg D, Kremer I. Identifying what matters to people with and at risk for Alzheimer's disease and their care partners: concept elicitation and item development. Poster presented at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting; December 6, 2019. San Diego, CA.

Tahami Monfared AA, Stull K, Zhang Q. Staging early Alzheimer's disease using the Alzheimer's Disease Composite Score (ADCOMS). Poster presented at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting; December 2019. San Diego, CA.

Ervin C, Thach A, Lee A, Navia B, Evans E, Doward L. Refinement of the treatment preference questionnaire in adults with Parkinson's Disease and off-episodes. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Nov; 22(S3):S756. doi: 10.1016/j.jval.2019.09.1870

Lewis S, Romano C, De Bruecker G, Murrough JW, Shelton R, Singh JB, Jamieson C. Analysis of clinical trial exit interview data in patients with treatment-resistant depression. Patient. 2019 Oct;12(5):527-37. doi: 10.1007/s40271-019-00369-8

Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019 Oct;39(12):1518-34. doi: 10.1177/0333102419851855

Ervin C, Sutphin J, Thach A, Lee A, Mansfield C, Coulter J. Patient insights into the burden of OFF-episodes in Parkinson's disease: qualitative interviews. Poster presented at the 2019 International Congress of Parkinson’s Disease and Movement Disorders Conference; September 23, 2019. Nice, France.

Poulos C, Wakeford C, Kinter E, Mange B, Schenk T. Preferences of patients for features of injectable, oral, and infused disease-modifying treatments for relapse-remitting multiple sclerosis. Poster presented at the 2019 ISPOR Latin America Conference; September 13, 2019. Bogota, Colombia.

Forns J, Layton JB, Ritchey ME. Identifying psychosis in patients with dementia: not a hallucination or delusion, the challenge really exists. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 24(S2):214. doi: 10.1002/pds.4864

Margulis AV, Hernandez-Diaz S, McElrath T, Rothman KJ, Plana E, Almqvist C, D'Onofrio BM, Oberg AS. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS One. 2019 Aug 5;14(8):e0214180. doi: 10.1371/journal.pone.0214180

Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, Gutierrez L, Chirila C, Deltour N. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019 Aug;33(4):311-9. doi: 10.1007/s40290-019-00291-2

Vradenburg G, DiBenedetti DB, Hauber B, Slota C, Wronski SL, Comer M, Callahan LF, Winfield J, Rubino I, Krasa HB, Hartry A, Wieberg BA, Kremer IN, Lappin D, Martin AD, Frangiosa T, Biggar V. Findings from the Alzheimer' Disease Patient and Caregiver Engagement (AD PACE) initiative's what matters most qualitative study. Poster presented at the 2019 Alzheimer's Association International Conference (AAIC); July 17, 2019. Los Angeles, CA.

Costello J, Njue A, Lyall M, Heyes A, Mahler N, Philbin M, Nazareth T. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials. Degener Neurol Neuromuscul Dis. 2019 Jul 1;9:55-78. doi: 10.2147/DNND.S208815

Paquin RS, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, Martin AS, Morris C, Rensch C, Ricotti V, Russo LJ, Sadosky A, Smith EC, Peay H. Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients. Orphanet J Rare Dis. 2019 May 9;14(1):102. doi: 10.1186/s13023-019-1069-6

Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Martin AS, Rensch C, Smith E, Ricotti V, Beaverson K, Wand H, Mansfield C. Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents. PLoS One. 2019 May 1;14(5):e0213649. doi: 10.1371/journal.pone.0213649